The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1.
about
Mutant ubiquitin found in Alzheimer's disease causes neuritic beading of mitochondria in association with neuronal degenerationThe ubiquitin proteasomal system: a potential target for the management of Alzheimer's diseaseMisframed ubiquitin and impaired protein quality control: an early event in Alzheimer's diseaseMutant ubiquitin UBB+1 induces mitochondrial fusion by destabilizing mitochondrial fission-specific proteins and confers resistance to oxidative stress-induced cell death in astrocytic cellsDisease-associated mutant ubiquitin causes proteasomal impairment and enhances the toxicity of protein aggregates.Expansion of the mycobacterial "PUPylome"Ubiquitin proteasome system as a pharmacological target in neurodegeneration.Protein quality control in neurodegeneration: walking the tight rope between health and disease.Commonalities in the genetics of Alzheimer's disease and Parkinson's disease.The therapeutic potential of microRNAs in nervous system damage, degeneration, and repair.Review: unchained maladie - a reassessment of the role of Ubb(+1) -capped polyubiquitin chains in Alzheimer's disease.The mechanisms of Mallory-Denk body formation are similar to the formation of aggresomes in Alzheimer's disease and other neurodegenerative disorders.Mutant ubiquitin attenuates interleukin-1β- and tumor necrosis factor-α-induced pro-inflammatory signaling in human astrocytic cells.Low levels of mutant ubiquitin are degraded by the proteasome in vivo.The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.Detecting the genetic link between Alzheimer's disease and obesity using bioinformatics analysis of GWAS data.Mutant ubiquitin-mediated beta-secretase stability via activation of caspase-3 is related to beta-amyloid accumulation in ischemic striatum in rats.Conformational equilibria of bulged sites in duplex DNA studied by EPR spectroscopyAnalysis of gene expression in Parkinson's disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death.Mutant ubiquitin and p62 immunoreactivity in cases of combined multiple system atrophy and Alzheimer's disease.
P2860
Q24311376-0592B2A5-7104-46E9-B768-4838B313FB41Q26749321-19B2CD50-88D7-4956-83FA-D43246E95CC3Q26782999-8838D5F4-DF85-4AE7-8BCC-D3666CEA1433Q28539822-117B4D8B-3F73-46F6-9114-C2E9CD08C97DQ33408783-71D46DE5-D6C9-49E9-A8ED-645394D8ABCBQ33757745-28D12CD1-4DDF-4E9B-AB7A-BC0F17288CB4Q36607342-786301CB-C462-4F6D-905A-E58676F2C717Q37044669-D33B0463-B692-473D-9BED-71241633428BQ37352061-6BAB8DA1-AAAD-42B2-8E59-BD70969AB3A9Q37376129-B7B7C3BC-3E9F-4A33-99DB-A91D49857E3EQ37955915-EF23026A-C68E-4483-8A0C-0C0AC8D668F5Q38805509-1EAB31ED-1FA9-46AD-BE2E-4035999AB733Q39127443-D1A111FA-1469-4552-9C74-1958711355F0Q39722990-EA72BAC1-BBB2-4EB6-8EA8-0B3FF33A0044Q39849106-CC5635F6-E5B8-4329-AC5C-6BB6BC69A3CEQ41348580-FE03112C-A03B-4E57-B771-87827168C951Q41790317-AEA6B6E9-5FAE-44FA-A9ED-695B44626C5CQ42236765-AF600621-4CB4-4FCC-9C79-07EF59B5F585Q46608005-AF38B0E0-DD7C-4568-AC0A-2F3FE62FF99DQ48304039-67A24371-E44D-4F32-99D9-79AC92B4CED8
P2860
The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The proteasome in Alzheimer's ...... e: lessons from ubiquitin B+1.
@ast
The proteasome in Alzheimer's ...... e: lessons from ubiquitin B+1.
@en
type
label
The proteasome in Alzheimer's ...... e: lessons from ubiquitin B+1.
@ast
The proteasome in Alzheimer's ...... e: lessons from ubiquitin B+1.
@en
prefLabel
The proteasome in Alzheimer's ...... e: lessons from ubiquitin B+1.
@ast
The proteasome in Alzheimer's ...... e: lessons from ubiquitin B+1.
@en
P1476
The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1
@en
P2093
David F Fischer
Fred W van Leeuwen
P304
P356
10.1016/J.MOLMED.2005.09.001
P50
P577
2005-10-06T00:00:00Z